
Product Sheet



Yalelaan 1 3584 CL Utrecht The Netherlands +31 30 253 3421 www.qvquality.com KvK: 30274082 VAT: 8215.17.168 NL88 RABO0153194936

C-C chemokine receptor type 2 (CCR2)

Catalogue no.: Clone name:	Q124c 2G5
Product: Target:	VHH directed against CCR2 The C-C chemokine receptor type 2 (CCR2 or CD192, UniProt P41597) is a 7- transmembrane spanning class A (rhodopsin-like) G protein-coupled receptor (GPCR). CCR2 has at least four human chemokine ligands, of which CCL2 is the most potent ¹ . CCR2 is predominantly expressed on monocytes and regulates (patho-)physiological inflammatory processes ² . Upregulated CCR2/CCL2 signaling is associated with cancer progression and metastasis, as well as inflammatory diseases ^{3,4} .
Source:	Recombinant monoclonal VHH (Llama glama), purified from <i>S. cerevisiae</i> using affinity chromatography. Immunization with CCR2b-expressing lipoparticles. Phage-display selection on lipoparticles with total elution.
Specificity:	Q124 binds to the extracellular part of human CCR2b and competes with clinically tested conventional antibody Plozalizumab.
Formulation:	0.2 μm filtered solution in PBS. The product is equipped with a C-terminal C-Direct tag with an unpaired cysteine for directional conjugation.
Mol. Weight: Ext. Coeff. (ε): A ₂₈₀ at 1g/L:	15509 kDa 24535 M ⁻¹ cm ⁻¹ 1.6
Storage:	Shipped on blue ice. Store at -20 $^{\circ}$ C (aliquots). Addition of 0.02% sodium azide is optional.
Applications:	ELISA, flow cytometry, most likely antagonism (not tested)
Examples:	
	100- 80- 100 (%) 100- (10) (%) 100- (10) (%) 100- (%) 100-(%) 100- (%) 100-(%) 100



Binding of Q124 (2G5) to CCR2b in HEK293-derived lipoparticles (left). Binding of Q124c-HL555 to N-terminally luciferase-tagged CCR2b (middle). Displacement of clinically tested CCR2 antibody Plozalizumab by Q124 in ELISA (right).

References: 1 Shao et al. (2022) Cell Discov. 8:44.

2 Yamasaki et al (2011) Clin. Exp. Neuroimmunol. 3, 16-29.

3 Fei et al (2021) Front Immunol. 12, 771210. 4 Pozzi et al (2019) Adv. Drug Deliv. Rev. 209, 115318.